Karo Pharma AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Karo Pharma AB - overview
Established
1987
Location
Stockholm, -, Sweden
Primary Industry
Pharmaceuticals
About
Based in Sweden, Karo Pharma AB specializes in providing healthcare solutions through a range of branded over-the-counter products that address various health needs. Karo Pharma AB, founded in 1987, operates from its headquarters in Stockholm, Sweden, focusing on consumer healthcare products. In April 2025, KKR agreed to acquire Karo Pharma AB from EQT, although the financial terms were not disclosed. CEO Christoffer Lorenzen is currently leading the company through this transition.
Karo Pharma offers a variety of branded healthcare products, catering to everyday health issues such as skin, foot, intimate, and digestive health. Their portfolio includes products like Remescar for skin health, Lamisil for foot health, and multi-Gyn for intimate health. The company distributes its products across over 90 countries, with a strong presence in the European and Nordic regions, providing accessible healthcare solutions to consumers. The company generates revenue primarily through sales of OTC and prescription medicines across Europe and globally.
Its business model leverages strong brand equity, pharmacy partnerships, and e-commerce channels. Karo Pharma's acquisition by KKR in April 2025 positions the company to pursue further growth, aiming to enhance its value as a strategic partner. The funding will be utilized to support the development of new products and expansion efforts, although specific upcoming product launches and geographic markets targeted for growth have not been detailed.
Current Investors
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare, Dermatology, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.karohealthcare.com/
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Karo Pharma AB - timeline of key events
Karo Pharma AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 33,173,000 | 47,029,000 | 30,060,000 | 69,095,000 | 347,261,000 | 657,606,000 | 1,615,109,000 | 1,901,196,000 | 2,882,867,000 | 2,961,354,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | 41.8% | (36.1%) | 129.9% | 402.6% | 89.4% | 145.6% | 17.7% | 51.6% | 2.7% | - | - | - |
| EBITDA (USD) | (228,750,000) | (98,001,000) | (20,824,000) | (57,588,000) | (71,710,000) | 51,510,000 | 143,040,000 | 632,189,000 | 491,857,000 | 724,950,000 | 771,844,000 | - | - | - |
| Operating Income (USD) | (231,159,000) | (99,749,000) | (22,258,000) | (59,455,000) | (74,863,000) | 29,573,000 | 79,904,000 | 414,320,000 | 172,102,000 | 230,306,000 | 205,905,000 | - | - | - |
| Operating Margin | - | (300.7%) | (47.3%) | (197.8%) | (108.3%) | 8.5% | 12.2% | 25.7% | 9.1% | 8.0% | 7.0% | - | - | - |
| % EBITDA Margin | - | (295.4%) | (44.3%) | (191.6%) | (103.8%) | 14.8% | 21.8% | 39.1% | 25.9% | 25.1% | 26.1% | - | - | - |
| NET Income (USD) | (226,626,000) | (98,254,000) | (22,078,000) | (59,282,000) | (78,191,000) | 95,556,000 | 14,505,000 | 657,392,000 | 8,941,000 | 82,905,000 | (16,990,000) | - | - | - |
| % Net Margin | - | (296.2%) | (46.9%) | (197.2%) | (113.2%) | 27.5% | 2.2% | 40.7% | 0.5% | 2.9% | (0.6%) | - | - | - |
Karo Pharma AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Karo Pharma AB | - | ||||||||
| Add-on | Completed | Del Decus Enterprises Ltd. | - | ||||||||
| Add-on | Completed | E45 Brand | - | ||||||||
| Add-on, Trade Sale | Announced | Sylphar NV | - | ||||||||
| Add-on | Completed | Ultrasicc | - |
Displaying 1 - 5 of 20
Karo Pharma AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.